HI SB2181

Permits manufacturers of investigational drugs and biological products to make them available to terminally ill patients beginning January 1, 2017, without requiring Food and Drug Administration approval.

Establishes "eligible patient" requirements including having a terminal illness, exhausting all FDA-approved treatment options, being unable to access clinical trials within 100 miles or accepted within one week, and obtaining physician recommendation and written informed consent.

Allows manufacturers to provide investigational drugs at no cost or require patients to pay manufacturing costs; prohibits requirement of compensation beyond actual costs.

Protects health care providers from license revocation, suspension, or other disciplinary action by state licensing boards for recommending investigational drugs to eligible patients with terminal illness.

Creates liability protections for manufacturers and other entities involved in patient care from lawsuits regarding harm from investigational drugs, except in cases of failure to exercise reasonable care.